Legal Representation
Attorney
Jong Park
USPTO Deadlines 0 active
All 4 deadline(s) have been cleared by subsequent events.
No active deadlines at this time.
Application History
25 events| Date | Code | Type | Description |
|---|---|---|---|
| Aug 30, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 30, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jul 26, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Jul 25, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Jul 11, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Jul 5, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 14, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Jun 14, 2022 | IUAF | S | USE AMENDMENT FILED |
| Apr 26, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Mar 1, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Mar 1, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Feb 9, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jan 24, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jan 21, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jan 21, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 21, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Aug 19, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Aug 19, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Aug 19, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jul 23, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Jul 23, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jul 23, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Jul 23, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Apr 13, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jan 16, 2021 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cancer cells; Cells for medical or clinical use; Pharmaceutical preparations for activating cellular function; Biological preparations for the treatment of immune system related disorders; Biological preparations for the treatment of cancer; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for tumor treatment; Vaccines; Pharmaceutical preparations for the treatment of cancers with T cells; Pharmaceutical preparations for the treatment of cancers with CAR-T cells
First Use Anywhere:
Jan 7, 2021
First Use in Commerce:
Apr 27, 2022
Class 042
Product development in the field of cell therapy; biomedical research services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; product development, namely, biologics development; biological research and analysis; consultancy in the field of analysis of biology sequence processing for medical research purposes; multiple nucleotide sequence analysis for scientific research purposes; DNA sequence analysis for scientific research purposes; medical research services in the field of cell separation; medical research in the field of biologics
First Use Anywhere:
Jan 7, 2022
First Use in Commerce:
Apr 27, 2022
Classification
International Classes
005
042